

# The effect of *Wolbachia* on dengue dynamics in the presence of two serotypes of dengue: symmetric and asymmetric epidemiological characteristics

M. Z. NDI<sup>1,2\*</sup>, D. ALLINGHAM<sup>1</sup>, R. I. HICKSON<sup>1,3</sup> AND K. GLASS<sup>4</sup>

<sup>1</sup> *School of Mathematical and Physical Sciences, The University of Newcastle, Australia*

<sup>2</sup> *Department of Mathematics, Nusa Cendana University, Kupang-NTT, Indonesia*

<sup>3</sup> *IBM Research – Australia, Melbourne, Australia*

<sup>4</sup> *National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia*

*Received 20 August 2015; Final revision 10 March 2016; Accepted 31 March 2016;  
first published online 21 April 2016*

## SUMMARY

An innovative strategy to reduce dengue transmission uses the bacterium *Wolbachia*. We analysed the effects of *Wolbachia* on dengue transmission dynamics in the presence of two serotypes of dengue using a mathematical model, allowing for differences in the epidemiological characteristics of the serotypes. We found that *Wolbachia* has a greater effect on secondary infections than on primary infections across a range of epidemiological characteristics. If one serotype is more transmissible than the other, it will dominate primary infections and *Wolbachia* will be less effective at reducing secondary infections of either serotype. Differences in the antibody-dependent enhancement of the two serotypes have considerably less effect on the benefits of *Wolbachia* than differences in transmission probability. Even if the antibody-dependent enhancement rate is high, *Wolbachia* is still effective in reducing dengue. Our findings suggest that *Wolbachia* will be effective in the presence of more than one serotype of dengue; however, a better understanding of serotype-specific differences in transmission probability may be needed to optimize delivery of a *Wolbachia* intervention.

**Key words:** Dengue, mathematical model, multiple serotypes, reduction, *Wolbachia*.

## INTRODUCTION

The increasing number of dengue cases worldwide and its re-appearance in dengue-free countries demonstrate the global threat it poses. Recent estimates are that dengue results in 390 million individuals infected annually [1].

Dengue, which is transmitted mainly by *Aedes aegypti* mosquitoes, is caused by four different virus serotypes. Individuals obtain lifelong immunity to

the serotype they are infected with, but do not have immunity to other serotypes. When infected by a second serotype, individuals are at greater risk of severe forms of dengue, such as dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS) [2]. Patients with DHF have viral levels 100–1000 times that of non-DHF patients [3]. This higher viral load is due to a phenomenon known as antibody-dependent enhancement (ADE), and is associated with higher transmissibility. In the majority of dengue endemic regions, more than one dengue serotype circulates, with dominant serotypes varying over time [4], thus increasing the opportunity for individuals to develop DHF or DSS.

Traditional strategies for dengue control such as insecticides have been found to be unsustainable [5]

\* Author for correspondence: Dr M. Z. Ndi, Department of Mathematics, Nusa Cendana University, Kupang-NTT, Indonesia, 85361.  
(Email: meksianis.ndii@alumni.anu.edu.au)

particularly in the developing world, and thus an innovative biological strategy against dengue has been proposed using the *Wolbachia* bacterium [6–10]. Mosquitoes carrying *Wolbachia* have lower levels of dengue virus in their salivary glands, and thus are less likely to transmit the virus to humans [6, 10]. *Wolbachia* also reduces the mosquito's lifespan [6], and hence mosquitoes have less time to transmit dengue. Additionally, the bacterium also reduces the reproductive rate of mosquitoes [6] and causes an effect called bendy proboscis which results in a reduced biting rate [11]. Mosquitoes carrying the bacterium are still viable in the wild, since *Wolbachia* gives female mosquitoes a reproductive advantage known as cytoplasmic incompatibility, whereby *Wolbachia*-carrying females can reproduce with non-*Wolbachia* or *Wolbachia*-carrying males, but non-*Wolbachia* females can only reproduce successfully when mating with non-*Wolbachia* males. Because *Wolbachia* in male mosquitoes modifies the sperm of their host, a pairing between a non-*Wolbachia* female and a *Wolbachia*-carrying male may not result in embryonic development [6, 12]. The results from mathematical models have shown that *Wolbachia*-carrying mosquitoes are likely to persist in the wild [13–16], and field experiments have confirmed that *Wolbachia*-carrying mosquitoes persist and can become established [7, 8].

Modelling studies suggest that *Wolbachia* may reduce dengue by 50–90%, with greater effects if the reproduction number is not large [14, 17]. These studies did not consider the effect of *Wolbachia* on dengue transmission dynamics in the presence of more than one serotype of dengue. The effect of multiple serotypes may be of importance because interactions between serotypes of dengue may affect dengue transmission dynamics. Disease severity is known to differ between serotypes [3], although estimates of the basic reproduction number from serological data showed relatively little difference between serotypes [18, 19].

Here we develop a two-serotype mathematical model of dengue transmission and explore symmetric and asymmetric epidemiological characteristics between serotypes. That is, when serotypes exhibit the same epidemiological parameter values, and when there are differences. We focus in particular on the ADE factor and the transmission probability (TP), and compare the effect of *Wolbachia* on both primary and secondary infections. Our model provides insights into the effectiveness of the *Wolbachia* intervention on dengue dynamics when more than one serotype of dengue is circulating in the population.

## METHODS

There are two aspects to our methods, the mathematical model and how we measure the effectiveness of the *Wolbachia* intervention. Throughout the paper, serotypes 1 and 2 refer to two different dengue serotypes but do not specifically refer to the DEN1 and DEN2 viruses.


### Mathematical model

The dynamics of two serotypes of dengue in the presence of *Wolbachia* were studied using a deterministic SEIR mathematical model that builds on the model by Ndii *et al.* [14]. As we are particularly interested in determining the efficacy of *Wolbachia* once mosquitoes carrying *Wolbachia* establish and persist in the wild [7, 8], we do not consider the transmission dynamics of dengue during transient periods as *Wolbachia* becomes established. Full details of the model and parameters are given in the Supplementary material, and a diagram showing states and transitions in the model is provided in Figure 1.

Human disease states in the model include Susceptible, Exposed, Infectious and Recovered, and we also include a temporary immunity class,  $X$ , following primary infection, where individuals have a short period of temporary immunity to all serotypes before being susceptible to the serotypes that they have not previously been infected with. The period of temporary immunity is taken to be 6 months [20]. We assume a constant human population of 150 000, which approximates that of Cairns, Australia, which was used in our parameter estimation [14], and also assume no deaths due to dengue, so that the birth and death rates of humans are the same.

Mosquito states in the model include an aquatic stage as well as Susceptible, Exposed and Infectious adult mosquitoes, with subscripts  $N$  and  $W$  indicating non-*Wolbachia* and *Wolbachia* mosquitoes. Although many parameters describing mosquito behaviour may depend on seasonality, in earlier work we found that the mosquito death rate is the most influential parameter [14] and hence this is the only parameter that is seasonally forced.

We simulate the model without dengue using initial conditions  $S_{H0} = 150000$ ,  $A_{N0} = S_{N0} = 3 \times S_{H0}$  and  $S_{W0} = 2 \times S_N$  until the mosquito population reaches a stable state, and then use those mosquito populations as new initial conditions for our simulations including dengue. To ensure that the epidemics do not




**Fig. 1.** Flowchart for the two-serotype dengue transmission model in the presence of *Wolbachia*-carrying mosquitoes. Solid lines denote progression between states, dashed lines denote transmission routes. Subscripts *H*, *N*, and *W* represent human, non-*Wolbachia* and *Wolbachia*-carrying mosquitoes, respectively, with categories of Susceptible (*S*), Exposed (*E*), and Infectious (*I*) for both mosquitoes and humans, aquatic stage for mosquitoes, and Recovered (*R*) and temporarily immune (*X*) for humans. Parameters in the diagram are described in detail in Supplementary Table S1.

occur when the infected population is <1 individual, the infected population is set to zero if it falls below a threshold of 0.5 individuals. This is a deterministic proxy for stochastic fade out.

**Measurement of *Wolbachia* performance and dengue introduction scenarios**

The performance of *Wolbachia* is assessed by comparing the relative difference between the outbreak size in the absence and presence of *Wolbachia*-carrying mosquitoes. Because only one dengue serotype generally dominates a yearly outbreak [4], humans carrying dengue serotype

1 are introduced weekly into the population for a 1-year period, and then individuals carrying serotype 2 are introduced weekly into the population in the subsequent year. Since we assume a constant human population, when the infected individuals are introduced through importation, the same numbers of individuals are subtracted from the susceptible population. The introduction process is repeated until the human infected populations remain the same for 75 years. Epidemiological characteristics of interest are the ADE factor and TP. We investigate their effect on outbreak sizes, separately and together, assuming they have the same values for both serotypes. Then we



**Fig. 2.** The effect of changes in the antibody-dependent enhancement (ADE) factor for both dengue serotypes under the first scenario of dengue introduction. All plots show overall (solid red lines), primary (blue dashed line) and secondary (black dash-dot line) infections. Plots (a) and (b) show the outbreak size in the absence and presence of *Wolbachia*-carrying mosquitoes, respectively. Plot (c) shows the proportional reduction in dengue due to *Wolbachia*.

investigate the case where serotype 2 has a higher TP or a higher ADE level. As ADE results in higher viral load [3], it increases the TP. Although they are related, we vary these two parameters independently to explore their effects on primary and secondary infections.


## RESULTS

The results below are divided into those for symmetric epidemiological characteristics between the two dengue serotypes, and the results where epidemiological characteristics differ (the asymmetric case).

### Symmetric epidemiological characteristics

Figure 2 presents the effect of *Wolbachia* on the outbreak size due to primary and secondary infections when both serotypes have the same epidemiological characteristics. The overall outbreak size is simply the sum of the outbreak sizes due to primary and secondary infections. As expected, the outbreak size in the absence of *Wolbachia*-carrying mosquitoes is always higher than in the presence of *Wolbachia*-carrying mosquitoes.

As the ADE rate increases, the outbreak sizes in the absence and presence of *Wolbachia*-carrying mosquitoes also increase, while the proportional reduction



**Fig. 3.** Contour plot showing simultaneous changes to the antibody-dependent enhancement (ADE) factor and transmission probability. The top and middle plots give the outbreak size in the absence and presence of *Wolbachia*-carrying mosquitoes. The bottom plot shows the proportional reduction in dengue due to *Wolbachia*.


in dengue due to *Wolbachia* decreases (Fig. 2). The reduction in secondary infections is higher than that of primary infections, with up to 78% reduction in secondary infections compared to  $\approx 45\%$  in primary infections.

When both ADE and TP are varied (Fig. 3), in the absence of *Wolbachia*-carrying mosquitoes, epidemics do not occur when TP is low (between 0 and 0.1). ADE has relatively little effect on the reduction in dengue due to *Wolbachia*. In the presence of *Wolbachia*-carrying mosquitoes, epidemics do not occur unless  $TP > 0.18$ . This means that the presence of *Wolbachia*-carrying mosquitoes raises the threshold value of TP at which epidemics occur. The maximum reduction in dengue due

to *Wolbachia* is around 70–80% which occurs when TP is between 0.16 and 0.23. If TP is high ( $>0.23$ ), *Wolbachia* becomes less effective in reducing dengue. Qualitatively similar results are obtained when considering primary and secondary infections (Supplementary Figs S1 and S2), although there is potential for greater reduction in secondary infections than primary infections.

#### Asymmetric epidemiological characteristics

As the ADE factor of serotype 2 increases relative to that of serotype 1, primary infections due to serotype 2 increase and there is a slight decline in secondary infections (Fig. 4) in the absence of *Wolbachia*-carrying




**Fig. 4.** The effect of changes in the antibody-dependent enhancement (ADE) factor for serotype 2 when the ADE for serotype 1 is fixed. All plots show overall (solid red lines), primary (dashed blue lines) and secondary (dash-dot black lines) infections. Plots show the outbreak size in the absence (*a, d*) and presence (*b, e*) of *Wolbachia*-carrying mosquitoes. Plots (*c*) and (*f*) show the proportional reduction in dengue incidence due to *Wolbachia*. The left-hand plots (*a-c*) show serotype 1 and the right-hand plots (*d-f*) show serotype 2.

mosquitoes. The same behaviour is found in the presence of *Wolbachia*-carrying mosquitoes, except that the outbreak size for secondary infections with serotype 2 slightly increases. In contrast, primary infections due to serotype 1 decrease and secondary infections increase.

Interestingly, the overall effect is of similar total case numbers due to serotype 1 as the ADE of serotype 2 increases, because the decrease in primary infections is offset by an increase in secondary

infections. The performance of *Wolbachia* in reducing primary infections of serotype 2 varies between 40% and 45% and that of serotype 1 between 39% and 45%. The number of secondary infections of serotype 2 is reduced by 70–78% and that of serotype 1 is reduced by 76–78%. The upper bounds in the reduction in the number of dengue cases due to *Wolbachia* are the same for both serotypes because the maximum reduction in dengue cases occurs when the ADE factor of both serotypes are equal.



**Fig. 5.** The effect of changes in the transmission probability of serotype 2 while the transmission probability of serotype 1 is fixed. All plots show the overall (solid red lines), primary (dashed blue lines) and secondary (dash-dot black lines) infections. Plots show the outbreak size in the absence (*a, d*) and presence (*b, e*) of *Wolbachia*-carrying mosquitoes. Plots (*c*) and (*f*) show the proportional reduction in dengue incidence due to *Wolbachia*. The left-hand plots (*a–c*) show serotype 1 and the right-hand plots (*d–f*) show serotype 2.

Again, it is clear that the reduction in secondary cases due to *Wolbachia* is higher than that of primary cases.

If the TP of serotype 2 increases relative to that of serotype 1, the number of primary infections it causes increases greatly (Fig. 5). As the TP of serotype 2 increases, the number of primary infections due to serotype 1 decreases, while that of secondary infections increases. The overall outbreak size due to serotype 1 remains constant as the TP of serotype 2 increases because the increase in secondary infections due to serotype 1 is balanced by a decrease in primary

infections due to this serotype. Interestingly, in the presence of *Wolbachia*-carrying mosquitoes, although the number of primary infections due to serotype 1 decreases, the number of secondary infections due to serotype 2 slightly increases, but the latter is still lower than the former. The proportional reduction of primary infections of serotype 2 due to *Wolbachia* varies between 7% and 45%, and that of secondary infections varies between 47% and 78%. The overall reduction of dengue infections caused by serotype 2 varies between 13% and 58%. Although serotype 1 is

less transmissible, an increase in TP of serotype 2 results in a decline in *Wolbachia* performance in reducing secondary infections caused by serotype 1. The presence of *Wolbachia*-carrying mosquitoes still reduces secondary infections caused by serotype 1 by >60%, although *Wolbachia* reduces primary infections due to serotype 1 by only around 38–45%.

## DISCUSSION AND CONCLUSIONS

The key results of this paper are that *Wolbachia* can reduce primary and secondary dengue infections, although the effects decline if one serotype is significantly more transmissible than the other. In particular, a significant reduction in secondary infections of up to 78% can be achieved using the *Wolbachia* intervention. This is of great importance for public health as secondary infections have a higher risk of developing the more severe forms of dengue. Although the potential for higher transmissibility of secondary dengue cases due to ADE influences the effectiveness of *Wolbachia*, the TP remains the key parameter affecting dengue transmission dynamics.

When dengue subtypes have the same epidemiological characteristics, we find that the ADE factor does not noticeably affect the effectiveness of *Wolbachia* except where TP is high. When  $TP < 0.14$ , an outbreak does not take off, so that the number of infectious humans is dominated by imported cases. When  $TP \geq 0.14$ , an outbreak will take off. The maximum reduction in dengue cases is obtained for TPs in the range 0.14–0.22, and considerable reductions in secondary infections of 60–80% are achieved. This implies *Wolbachia* will be most effective in reducing dengue transmission if dengue serotypes are not strongly transmissible, which is similar to the findings of Ndi *et al.* [14] for a single serotype. TP is one of the parameters that regulate the basic reproduction number, which means that a higher TP typically indicates a higher reproduction number. Hence, our result is consistent with the finding by Hughes & Britton [21] and Ferguson *et al.* [17] that *Wolbachia* will be effective if the basic reproduction number is not too high.

When the epidemiological characteristics of dengue serotypes differ, we find a shift towards greater numbers of primary infections of the subtype with the higher enhancement rate or higher TP. Where only the ADE factor differs between serotypes, we find relatively little decline in the effectiveness of *Wolbachia*. However, if one serotype is more

transmissible than the other, the effectiveness of *Wolbachia* against this serotype can drop below 20%, while still reducing dengue due the other serotype by  $\approx 60\%$ . Thus, *Wolbachia* may be less effective in reducing secondary infections if the TP of one of the serotypes is noticeably higher than that of the other.

If there are two serotypes circulating in the population and more individuals have primary infections with one of the serotypes, then it is likely that more individuals have secondary infections with the other serotype. Interestingly, we find that although the number of primary infections due to serotype 1 decreases in the presence of *Wolbachia*-carrying mosquitoes, the number of secondary infections caused by serotype 2 increases slightly. However, the number of secondary infections caused by serotype 2 is still lower than the number of primary infections caused by serotype 1. This may be for the following reasons. As ADE of serotype 2 increases, there are more individuals primarily infected with serotype 2 than serotype 1. The higher number of primary infections with serotype 2 affects the force of infection, resulting in a greater likelihood of secondary infection with serotype 2 for individuals previously infected with serotype 1. Hence, as ADE for serotype 2 increases, the number of secondary infections caused by serotype 2 increases. This implies that there is a complex interaction between variables regulating the force of infection. Note that similar behaviour is also found when varying the TP of serotype 2.

Our results imply that the introduction of *Wolbachia*-carrying mosquitoes into the population can potentially reduce dengue transmission. In particular, a greater reduction in secondary infections can be obtained. However, the effectiveness of *Wolbachia* in reducing dengue transmission may be lower when TP is higher. This finding suggests that this intervention may only be effective in regions with lower transmission strength. There are complex interactions between variables regulating the force of infection. These include the mosquito biting rate and TP. Further analysis of the effects of *Wolbachia* on these variables is required to enhance our understanding of *Wolbachia* effectiveness. Specific variables of interest include the mosquito biting rate and the level of virus in mosquitoes in particular when they are released into the field.

In this paper, we used a deterministic model which is appropriate for a large population such as that considered here. Consideration of stochastic effects may

be important for investigating small infected populations. We have also assumed a fairly simple serotype introduction pattern, with two serotypes dominating in alternate years. While our model simplifies the typical pattern of serotype introductions [22], it captures yearly variation in serotype introductions. We also tested other introduction patterns – including one in which one serotype is introduced more often than the other – and found broadly similar results. Our finding that differences in the ADE factor between serotypes has much less effect on dengue dynamics than differences in TP indicates that a better understanding of serotype-specific TPs may be needed to optimize delivery of *Wolbachia* interventions.

### SUPPLEMENTARY MATERIAL

For supplementary material accompanying this paper visit <http://dx.doi.org/10.1017/S0950268816000753>.

### ACKNOWLEDGEMENTS

M.Z.N. acknowledges the University of Newcastle for a PhD scholarship.

### DECLARATION OF INTEREST

None.

### REFERENCES

1. **Bhatt S, et al.** The global distribution and burden of dengue. *Nature* 2013; **496**: 504–507.
2. **Gubler DJ.** Dengue and dengue hemorrhagic fever. *Clinical Microbiology Reviews* 1998; **11**: 480–496.
3. **Vaughn DW, et al.** Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. *Journal of Infectious Diseases* 2000; **181**: 2–9.
4. **Limkittikul K, Brett J, L’Azou M.** Epidemiological trends of dengue disease in Thailand (2000–2011): a systematic literature review. *PLoS Neglected Tropical Diseases* 2014; **8**: e3241.
5. **Maciel-de-Freitas R, et al.** Undesirable consequences of insecticide resistance following *Aedes aegypti* control activities due to a dengue outbreak. *PLoS ONE* 2014; **9**: e92424.
6. **Walker T, et al.** The wMel *Wolbachia* strain blocks dengue and invades caged *Aedes aegypti* populations. *Nature* 2011; **476**: 450–453.
7. **Hoffmann AA, et al.** Successful establishment of *Wolbachia* in *Aedes* populations to suppress dengue transmission. *Nature* 2011; **476**: 454–457.
8. **Hoffmann AA, et al.** Stability of the WMel *Wolbachia* infection following invasion into *Aedes aegypti* populations. *PLoS Neglected Tropical Diseases* 2014; **8**: e3115.
9. **Hoffmann AA, Turelli M, Harshman LG.** Factors affecting the distribution of cytoplasmic incompatibility in *Drosophila simulans*. *Genetics* 1990; **126**: 933–948.
10. **Frentiu FD, et al.** Limited dengue virus replication in field-collected *Aedes aegypti* mosquitoes infected with *Wolbachia*. *PLoS Neglected Tropical Diseases* 2014; **8**: e2688.
11. **Turley AP, et al.** *Wolbachia* infection reduces blood-feeding success in the dengue fever mosquito, *Aedes aegypti*. *PLoS Neglected Tropical Diseases* 2009; **3**: e516.
12. **Werren JH.** Biology of *Wolbachia*. *Annual Review Entomology* 1997; **42**: 587–609.
13. **Ndi MZ, Hickson RI, Mercer GN.** Modelling the introduction of *Wolbachia* into *Aedes aegypti* to reduce dengue transmission. *ANZIAM Journal* 2012; **53**: 213–227.
14. **Ndi MZ, et al.** Modelling the transmission dynamics of dengue in the presence of *Wolbachia*. *Mathematical Biosciences* 2015; **262**: 157–166.
15. **Hancock PA, Sinkins SP, Godfray HCJ.** Population dynamic models of the spread of *Wolbachia*. *American Naturalist* 2011; **177**: 323–333.
16. **Chan MT, Kim P.** Modelling a *Wolbachia* invasion using a slow–fast dispersal reaction–diffusion approach. *Bulletin of Mathematical Biology* 2013; **75**: 1501–1523.
17. **Ferguson NM, et al.** Modeling the impact on virus transmission of *Wolbachia*-mediated blocking of dengue virus infection of *Aedes aegypti*. *Science Translational Medicine* 2015; **7**: 279ra37–279ra37.
18. **Ferguson NM, Donnelly CA, Anderson RM.** Transmission dynamics and epidemiology of dengue: insights from age-stratified seroprevalence surveys. *Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences* 1999; **354**: 757–768.
19. **Rodríguez-Barraquer I, et al.** Revisiting Rayong: shifting seroprofiles of dengue in Thailand and their implications for transmission and control. *American Journal of Epidemiology* 2014; **179**: 353–360.
20. **Wearing HJ, Rohani P.** Ecological and immunological determinants of dengue epidemics. *Proceedings of the National Academy of Sciences USA* 2006; **103**: 11802–11807.
21. **Hughes H, Britton NF.** Modelling the use of *Wolbachia* to control dengue fever transmission. *Bulletin of the Mathematical Biology* 2013; **75**: 796–818.
22. **Warrilow D, Northill JA, Pyke AT.** Sources of dengue viruses imported into Queensland, Australia, 2002–2010. *Emerging Infectious Diseases* 2012; **18**: 1850–1857.